Accelerating Therapeutic DiscoveryTM

News From The Alpha-1 Project

08
Arrowhead Pharmaceuticals Inc., has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

[Read More...]

24
Up to $162.5M in upfront, cost sharing and milestone payments, and escalating royalties into the high teens assuming exercise of the option   SAN DIEGO, May 30, 2019 /PRNewswire/ — Inhibrx, Inc. (“Inhibrx”), a clinical-stage ...

[Read More...]

03
Dicerna begin the clinical development phase of an A1AT deficiency-associated liver disease program

[Read More...]

30
Arrowhead Pharmaceuticals granted FAST TRACK status for first potential AATD liver disease therapeutic.

[Read More...]

17
Translational Science Highlight Scientists in NCATS' Assay Development and Screening Technology program are developing new methods for screening small molecules that could help researchers develop new treatments for many diseases. Collabo...

[Read More...]

Page 1 of 5First   Previous   [1]  2  3  4  5  Next   Last